The trial, run at the Otology Center of the Eye & ENT Hospital of Fudan University from October 2023 to May 2025, tested the “Vertigo Station” app against in-person guidance over a 90-day recovery period. jmir.org reported that the adjusted difference between groups in Dizziness Handicap Inventory change was −0.83 points — a margin with no clinical meaning, given a confidence interval spanning −8.79 to 7.13 and a P value of .84.
App-based care has improved outcomes in tuberculosis, obstructive sleep apnea, and urticaria management, and a 2018 report counted more than 325,000 health apps in app stores. For vestibular patients, the question was whether video-guided exercises and automated adherence monitoring could match a therapist’s hands-on coaching. This trial says: not measurably better, at least not for dizziness-specific quality of life.
- Patients recovering from vestibular schwannoma surgery did just as well with a rehab app as with in-person therapy — the app was not superior, but it was not worse either.
- Both approaches reduced dizziness-related disability over 90 days; the app simply added no measurable extra benefit.
- An early hint that app users had fewer balance problems in the first week vanished after proper statistical correction, so it should not be treated as proof.
Why Schwannoma Surgery Leaves Patients Dizzy
Vestibular schwannoma — once called acoustic neuroma — is a benign tumor arising from Schwann cells on the vestibulocochlear nerve, the cranial nerve carrying balance and hearing signals to the brain. It accounts for 6% to 7% of intracranial tumors, is usually unilateral, and typically announces itself with sensorineural hearing loss, tinnitus, and vertigo, the false sensation of self-motion.
Surgery removes the tumor but often sacrifices function on that side, producing what clinicians call acute unilateral vestibular loss. The mechanism of action of vestibular rehabilitation rests on central compensation: repeated gaze-stabilization, habituation, and balance exercises train the brain to recalibrate against the mismatched signals from the two inner ears.
The evidence base supports rehabilitation over no treatment — but only 25.5% of eligible patients receive any session, and just 15.2% complete a full course, largely because specialized therapists and facilities are unevenly distributed. That access gap is precisely what app-based delivery was designed to close.
Inside the Trial: App Versus Therapist
Sixty adults aged 18 to 70, all undergoing retrosigmoid tumor resection by the same lead surgeon, were randomized 1:1 with concealed allocation using sealed envelopes. The intervention group received guidance, symptom logging, and adherence monitoring through Vertigo Station, developed jointly by the Eye & ENT Hospital of Fudan University and The Second People’s Hospital of Shenzhen. Controls got face-to-face instruction, paper diaries, and a printed rehabilitation handbook.
Blinded raters assessed patients preoperatively and on postoperative days 7, 30, and 90. Of 60 randomized participants, 52 (86.7%) had day-90 Dizziness Handicap Inventory scores, and 49 (81.7%) had paired baseline and day-90 scores for the primary analysis. The sample was sized to detect an 18-point between-group difference, the minimal clinically important difference for the DHI.
| Outcome | Result | Interpretation |
|---|---|---|
| DHI change, baseline to day 90 | Adjusted difference −0.83 (95% CI −8.79 to 7.13); P=.84 | No significant between-group difference |
| VAS symptom scores, days 7/30/90 | All P>.05 | No significant differences |
| Postural symptoms, day 7 | 53.3% (16/30) app vs 83.3% (25/30) face-to-face | Unadjusted P=.03; Holm-adjusted P=.30 — exploratory only |
The day-7 postural finding deserves a note on statistical honesty. When researchers test many symptoms, some will look significant by chance; the Holm correction adjusts for this multiple-comparison problem. Once adjusted, the apparent early advantage of the app group dissolved to P=.30. The authors themselves label it exploratory and requiring confirmation.
What This Means for Patients Outside China
The trial was approved by the Ethics Committee of the Eye & ENT Hospital of Fudan University in April 2021, registered on the Chinese Clinical Trial Registry (ChiCTR2200056123), and conducted under Good Clinical Practice and the Declaration of Helsinki with informed consent from all participants.
The source report does not name a commercial funder; the app was developed jointly by two public Chinese hospitals, and readers should weigh that institutional involvement when interpreting the result.
Contraindications & When to Consult a Doctor
- People with neuromuscular disease, head or neck movement restrictions, or balance disorders from other causes were excluded from this trial; app-based programs may not be safe or appropriate for them without individual assessment.
A Measured Path Forward
The honest conclusion is one of equivalence, not failure. Both delivery modes improved dizziness outcomes over 90 days; the app simply did not outperform a therapist.
For the 58% to 75% of schwannoma surgery patients who experience imbalance and the up to 30% whose symptoms persist beyond a month, the access problem remains unsolved — and a well-designed app, even one offering no superiority, may still be the only option for the many patients who never reach a specialist.
The Eye & ENT Hospital of Fudan University, founded in 1952, is the first specialized hospital for eye, ear, nose, and throat care in China and the only tertiary class-A institution of its kind directly managed by the National Health Commission.
With 755 beds and a workforce of 2,008 employees, it operates under a “one hospital, two wings” model spanning multiple locations. Its otolaryngology department is designated a key discipline by the Ministry of Education, and the hospital hosts national-level laboratories in auditory medicine and endoscopic skull base tumor surgery — the surgical field relevant to the schwannoma patients in the trial.
References
- Chinese Clinical Trial Registry — ChiCTR2200056123
- Eye & ENT Hospital of Fudan University, Otology Center — trial protocol 2021-2021071-1
Readers should consult their treating physician before starting or changing any rehabilitation program.